Sabitar 49 mg+51 mg (Tablet)
Unit Price: ৳ 80.00 (2 x 10: ৳ 1,600.00)
Strip Price: ৳ 800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Reduces risk of cardiovascular death
- Reduces hospitalization for heart failure
- Treatment for symptomatic heart failure
- Administered in conjunction with other therapies
- Replacement for ACE inhibitor or other ARB
Pharmacology
- Contains neprilysin inhibitor and angiotensin receptor blocker
- Inhibits neprilysin via LBQ657
- Blocks angiotensin II type-1 receptor via valsartan
- Increases levels of peptides degraded by neprilysin
- Simultaneously inhibits effects of angiotensin II
Dosage & Administration
- Recommended starting dose for adults
- Dose adjustment for patients not taking ACEi or ARB
- Dose adjustment for severe renal impairment
- Recommended dose for pediatric patients
- Dose titration for pediatric patients based on weight
Interaction
- Should not be used with ACEi
- Avoid use with aliskiren in diabetes
- Interaction with potassium-sparing diuretics
- Interaction with NSAIDs
- Increased risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACEi or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in diabetes
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness not established in pediatric patients less than 1 year
- No relevant pharmacokinetic differences in elderly patients
- No dose adjustment required in mild hepatic impairment
- Not recommended in severe hepatic impairment
- No dose adjustment required in mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- May lower blood pressure
- Requires monitoring of serum creatinine
- Requires monitoring of serum potassium
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences in elderly patients
- Dose adjustment for severe renal impairment
- Dose adjustment for moderate hepatic impairment
- Not recommended in severe hepatic impairment
Overdose Effects
- Limited data available on overdosage
- Hypotension is a likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis
Storage Conditions
- Keep in a dry place
- Store below 30°C
- Protect from moisture
- Keep out of the reach of children